Hepatology最新文献

{"title":"Moving beyond the liver – proteomics as a molecular footprint of systemic damage in metabolic dysfunction-associated steatotic liver disease","authors":"Mary E. Rinella","doi":"10.1097/hep.0000000000001376","DOIUrl":"https://doi.org/10.1097/hep.0000000000001376","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"58 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Antibody-mediated rejection in liver transplantation following immune checkpoint inhibitors treatment","authors":"Beat Moeckli, Loyse Lanz, Manuel Rodríguez-Perálvarez, Stephanie Lacotte, Christian Toso","doi":"10.1097/hep.0000000000001375","DOIUrl":"https://doi.org/10.1097/hep.0000000000001375","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"55 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term mortality and extrahepatic outcomes in 1,096 children with MASLD: A retrospective cohort study","authors":"Jeffrey B. Schwimmer, Nhat Quang N. Thai, Sheila L. Noon, Patricia Ugalde-Nicalo, Sabina R. Anderson, Lauren F. Chun, Rhys S. David, Nidhi P. Goyal, Kimberly P. Newton, Eleanor G. Hansen, Bonnie Lin, Warren L. Shapiro, Andrew Wang, Elizabeth L. Yu, Cynthia A. Behling","doi":"10.1097/hep.0000000000001357","DOIUrl":"https://doi.org/10.1097/hep.0000000000001357","url":null,"abstract":"Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"7 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease","authors":"Naoto Fujiwara, Yuki Matsushita, Mina Tempaku, Yutaro Tachi, Genki Kimura, Kiyora Izuoka, Yuki Hayata, Satoshi Kawamura, Akiko Eguchi, Takuma Nakatsuka, Masaya Sato, Atsushi Ono, Eisuke Murakami, Masataka Tsuge, Shiro Oka, Akinobu Hayashi, Yoshifumi Hirokawa, Masatoshi Watanabe, Neehar D. Parikh, Amit G. Singal, Jorge A. Marrero, Yujin Hoshida, Shugo Mizuno, Ryosuke Tateishi, Kazuhiko Koike, Mitsuhiro Fujishiro, Hayato Nakagawa","doi":"10.1097/hep.0000000000001360","DOIUrl":"https://doi.org/10.1097/hep.0000000000001360","url":null,"abstract":"Background &amp; Aims: Hepatic fiber morphology may significantly enhance our understanding of molecular alterations in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to comprehensively characterize hepatic fiber morphological phenotypes in MASLD and their associated molecular alterations using multi-layer omics analyses. Approach &amp; Results: To quantify the morphological phenotypes of hepatic fibers, the artificial intelligence-based FibroNest algorithm (PharmaNest) was applied to 94 MASLD-affected liver biopsies, among which 12 (13%) had concurrent hepatocellular carcinoma (HCC). FibroNest identified 327 fiber phenotypes that were summarized into eight major principal components, named FibroPC1–8. Next, molecular alterations captured by morphological fiber phenotypes were evaluated by comparison with genome-wide transcriptomics of paired liver samples. Pathway analyses revealed that FibroPCs more sensitively captured MASLD-related molecular alterations, such as upregulation of interleukin-6 and susceptibility to resmetirom, compared with the histological fibrosis stage. Among them, FibroPC4, which reflects reticular fibers, was associated with a gene signature predictive of incident HCC from MASLD. Furthermore, we used a spatial single-cell transcriptome, CosMx, to reveal the cell-cell interactions driving MASLD pathogenesis, as captured by FibroPC4. CosMx revealed that the FibroPC4-rich microenvironment contains HCC-promoting hepatic stellate cells (HSCs) located adjacent to periportal endothelial cells (ECs). Neighboring cell analyses suggested that the HCC-promoting phenotype of HSCs was acquired by insulin growth factor-binding protein 7 (IGFBP-7) secreted from senescent periportal ECs. Consistently, <jats:italic toggle=\"yes\">in vitro</jats:italic> experiments showed that IGFBP-7 transformed HSCs into an HCC-promoting phenotype. Conclusions: Hepatic morphological fiber phenotyping can reveal the disease progression and underlying mechanisms of MASLD.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"71 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor: Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC","authors":"Rui Du, Yanfei Yang, Yuzhe Su, Shimeng Cui","doi":"10.1097/hep.0000000000001363","DOIUrl":"https://doi.org/10.1097/hep.0000000000001363","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"47 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction models for liver decompensation in compensated advanced chronic liver disease: a systematic review","authors":"Vincent Haghnejad, Laura Burke, Siham El Ouahabi, Richard Parker, Ian A. Rowe1","doi":"10.1097/hep.0000000000001359","DOIUrl":"https://doi.org/10.1097/hep.0000000000001359","url":null,"abstract":"Background and Aims: Identifying individuals with compensated advanced chronic liver disease (cACLD) at risk of decompensation allows for personalized therapy. However, predicting decompensation is challenging, and multiple models have been developed. This study systematically appraises the performance and clinical applications of published multivariable models predicting first decompensation in patients with cACLD or compensated cirrhosis. Approach and Results: We searched MEDLINE for liver decompensation prediction models from inception to December 2023. The research was registered with PROSPERO (CRD42023488395). Model risk of bias and applicability were assessed using the PROBAST tool, with results summarized via narrative synthesis. Reporting followed PRISMA and CHARMS guidelines. Sixteen studies (retrospective and prospective) were included. Seven focused on a single aetiology. No study specifically predicted outcomes in persons with alcohol-related liver disease. Outcome definitions varied, with some models predicting hepatocellular carcinoma together with decompensation. In total, 27 predictors were included in the models. The most frequent predictors were albumin, platelets, age, liver stiffness, bilirubin, international normalized ratio, and the presence of portal-hypertension-related findings during upper gastrointestinal endoscopy. All studies reported discrimination measures but only 10/16 evaluated calibration. External validation was conducted in 9/16 studies. Thirteen studies were rated as having a high overall risk of bias. Conclusions: For clinical utility, a predictive model must accurately describe future risks. Models for predicting decompensation in cACLD are often poorly described, infrequently include patients with ArLD, and lack external validation. These factors are barriers to the clinical utility and uptake of predictive models for first decompensation in patients with cACLD.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"91 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase","authors":"Jian Wang, Shaoqiu Zhang, Tao Fan, Chao Wu, Rui Huang","doi":"10.1097/hep.0000000000001365","DOIUrl":"https://doi.org/10.1097/hep.0000000000001365","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"17 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC","authors":"Qingbin Liu, Jingjing Qi, Yong Yu, Shulong Jiang","doi":"10.1097/hep.0000000000001364","DOIUrl":"https://doi.org/10.1097/hep.0000000000001364","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"108 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Late breaking abstracts","authors":"Philip Newsome, Arun Sanyal, Iris Kliers, Laura Østergaard, Michelle Long, Mette Kjær, Anna M.G. Cali, Elisabetta Bugianesi, Mary Rinella, Michael Roden, Vlad Ratziu","doi":"10.1097/hep.0000000000001323","DOIUrl":"https://doi.org/10.1097/hep.0000000000001323","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"1 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection","authors":"Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Junlong Dai, Yee-Kit Tse, Mandy Sze-Man Lai, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip","doi":"10.1097/hep.0000000000001354","DOIUrl":"https://doi.org/10.1097/hep.0000000000001354","url":null,"abstract":"Background &amp; Aims: The outcomes and benefits of antiviral therapy in patients with indeterminate phase HBeAg-negative chronic hepatitis B (CHB) are not well described in treatment guidelines. We examined hepatocellular carcinoma (HCC) risk among these patients. Approach &amp; Results: We identified all non-cirrhotic treatment-naïve patients with HBeAg-negative CHB who received ≥1 test for hepatitis B virus (HBV) DNA and HBeAg. HBeAg-negative indeterminate phase included abnormal alanine aminotransferase (ALT ≥40 IU/L) and low HBV DNA (&lt;2,000 IU/mL), or normal ALT (&lt;40 IU/L) and high HBV DNA (≥2,000 IU/mL). Cox model evaluated relationship between HBV phase and HCC risk, with antiviral therapy as time-dependent variable. In 17,287 patients (mean age 54.1 years, 50% male), 4,071 (24%) transitioned to HBeAg-negative chronic hepatitis, 8,722 (50%) remained in the indeterminate phase, and 4,494 (26%) moved to HBeAg-negative chronic infection over a median follow-up of 55.1 [interquartile range 21.3-105.4] months. Patients in the indeterminate phase had a significantly higher HCC risk than those in chronic infection (adjusted hazard ratio [aHR] 1.587, 95% CI 1.262-1.995). Among patients in the indeterminate phase, those with normal ALT and high HBV DNA had a higher HCC risk than those with abnormal ALT and low HBV DNA (aHR 1.377, 95% CI 1.007-1.883, <jats:italic toggle=\"yes\">p</jats:italic>=0.045). The 5-year cumulative HCC incidence showed no significant difference between treated and untreated patients in either group. Conclusions: In patients with indeterminate phase HBeAg-negative CHB, those with normal ALT and high HBV DNA showed a higher HCC risk than those with abnormal ALT and low HBV DNA, with no difference between treated and untreated patients in either group. Close monitoring with timely antiviral treatment may suffice to mitigate HCC risk in untreated patients.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"29 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}